BE study Design for Ri­va­rox­aban 20 mg [Design Issues]

posted by Tricky TAB – Bangladesh, 2022-07-04 13:33 (601 d 02:39 ago) – Posting: # 23103
Views: 2,068


The Design for Rivaroxaban 20 mg BE Study stated by US-FDA is as follows:

Single-dose, two-treatment, two-sequence, four-period, fully replicate crossover

Is it possible to go with Single-dose, two-treatment, two-sequence, two-period crossover study design?

Thank You!

Edit: Category changed; see also this post #1. Guidance linked. [Helmut]

Complete thread:

UA Flag
 Admin contact
22,911 posts in 4,806 threads, 1,635 registered users;
30 visitors (0 registered, 30 guests [including 4 identified bots]).
Forum time: 15:12 CET (Europe/Vienna)

The history of statistics is like a telephone directory:
the plot is boring, full of numbers and the cast is endless.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz